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The mycolyl transferase antigen 85 complex is a major secreted protein family from mycobacterial culture filtrate, demonstrating
powerful T cell stimulatory properties in most HIV-negative, tuberculin-positive volunteers with latent M.tuberculosis infection
and only weak responses in HIV-negative tuberculosis patients. Here, we have analyzed T cell reactivity against PPD and Ag85
in HIV-infected individuals, without or with clinical symptoms of tuberculosis, and in AIDS patients with disease caused by
nontuberculous mycobacteria. Whereas responses to PPD were not significantly diﬀerent in HIV-negative and HIV-positive
tuberculin-positive volunteers, responses to Ag85 were significantly decreased in the HIV-positive (CDC-A and CDC-B) group.
Tuberculosis patients demonstrated low T cell reactivity against Ag85, irrespective of HIV infection, and finally AIDS patients
suﬀering from NTM infections were completely nonreactive to Ag85. A one-year follow-up of twelve HIV-positive tuberculin-
positive individuals indicated a decreased reactivity against Ag85 in patients developing clinical tuberculosis, highlighting the
protective potential of this antigen.
1. Introduction
Mycobacterium tuberculosis (M. tuberculosis), the causative
agent of tuberculosis (TB), remains the largest single infec-
tious cause of death globally. Indeed, about one third of the
world population is infected with M. tuberculosis, and in
2008 an estimated 1.3 million people died of tuberculosis
and an estimated 9.3 million people developed the disease
worldwide (http://www.who.int/mediacentre/factsheets/fs104/
en/index.html). Administration for many decades of the
attenuated strain of M. bovis BCG (Bacillus Calmette-
Gue´rin) as a vaccine—which in 2000 covered 86% of
the world population [1]—has not been able to eradicate
this poverty-related sickness. The long duration of treat-
ment with a combination of three to four antibiotics, the
lack of compliance, and the unreliable drug supply have
been important causes for the emergence of multidrug
resistant (MDR) strains of M. tuberculosis [2]. Moreover,
at least one third of the more than 30 million people
infected with the human immunodeficiency virus HIV
worldwide are also infected with M. tuberculosis. HIV-
positive subjects are at increased risk to reactivate a latent
M. tuberculosis infection, even when CD4+ counts are still
relatively unaﬀected. While the risk to reactivate TB is in
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the order of 10% on a lifetime basis for HIV-negative
persons, there is an annual estimated risk of 10% for HIV-
M. tuberculosis coinfected subjects [3, 4]. In 2008, there
were 1.4 million HIV-positive tuberculosis patients globally
and 500,000 people died of HIV-associated TB http://www
.who.int/tb/challenges/hiv/factsheet hivtb 2009update.pdf.
It is clear that the development of improved prophylactic
and immunotherapeutic vaccines, which could be adminis-
tered to both immunocompetent and immunocompromised
people, is urgently needed to control the global threat of TB.
For this purpose, the identification of major antigens recog-
nized by the protective immune response against M. tuber-
culosis remains an essential step. This has led to the inves-
tigation, in preclinical animal models, of more than one-
hundred new vaccine candidates [5, 6], of which some have
now progressed to phase 1 and phase 2 clinical trials [7–9].
Among the secreted and surface-exposed proteins from the
pathogen, important for the elicitation of protective immune
responses against TB [10, 11], components of the secreted
Ag85 complex, a major protein fraction of all mycobacterial
culture filtrates, are among the most promising vaccine
candidates [12]. The Ag85 complex is a 30–32 kD family of
three proteins (Ag85A, Ag85B, and Ag85C), which all three
possess enzymatic mycolyl transferase activity involved in the
coupling of mycolic acids to the arabinogalactan of the cell
wall and in the biogenesis of cord factor [13, 14]. Ag85 is
considered to be a virulence factor as its expression is needed
for intracellular survival within macrophages [14]. On the
other hand, the Ag85 components are very immunogenic.
In mice, guinea pigs, and nonhuman primates, vaccination
with members of the Ag85 family was reported to stimulate
strong humoral and cell-mediated immune responses and
to confer significant protection against challenge with live
M. tuberculosis H37Rv [15–19]. We have previously reported
that the Ag85A protein induces strong T cell proliferation
and IFN-γ production in most healthy individuals latently
infected with M. tuberculosis/M. leprae [20, 21] and in BCG-
vaccinated mice [22] but not in patients suﬀering from
tuberculosis or lepromatous leprosy [23, 24]. Both Ag85A
and Ag85B are actually being tested in clinical phase 1 and
2 trials, respectively, as recombinant Modified Vaccinia Virus
in a BCG prime-MVA-Ag85A boost protocol [8, 25] or as a
subunit fusion protein vaccine coupled to ESAT-6 [7, 26].
The aim of this paper was to evaluate memory T cell
responses against Ag85 in a context of HIV infection by
measuring proliferative responses and IFN-γ secretion
upon in vitro stimulation of peripheral blood leukocytes. In
parallel, T cell responses were also analyzed against crude
mycobacterial antigen, that is, purified protein derivative
(PPD) and against polyclonal mitogens Phytohemagglutinin
(PHA) and Pokeweed Mitogen (PWM), as indicators of
overall immune status.
2. Materials and Methods
2.1. Subjects
2.1.1. Belgian Study. Twenty-three HIV-negative/tuberculin-
positive subjects were recruited among laboratory workers
of the WIV-ISP-IPH and the Hoˆpital Erasme, Brussels.
One subject had received prior BCG vaccination (not
performed on a routine basis in Belgium) whereas the
others were presenting with a latent M. tuberculosis infection
or were cured of pulmonary TB patients (three subjects).
Fifteen HIV-negative/tuberculin-negative subjects were also
recruited among laboratory workers of the WIV-ISP-IPH
and the Hoˆpital Erasme. Seventeen HIV-positive/tuberculin-
positive subjects without clinical symptoms of tuberculosis
(CDC-A) were recruited at the Hoˆpital Erasme (mean CD4+
counts: 454± 228/mm3). Ten AIDS patients presenting with
clinical signs of active tuberculosis were recruited at the
Hoˆpital Erasme; three suﬀered from pulmonary TB, five
from extrapulmonary TB, and two from pleural eﬀusion
(Mean CD4+ count: 202 ± 36/mm3). Finally seven AIDS
patients suﬀering from disease caused by mycobacteria other
than tuberculosis (NTM) (M. avium-intracellulare (n = 6)
or M. gordonae (n = 1)) were enrolled at the Hoˆpital Saint-
Pierre in Brussels (Mean CD4+ count: 11/mm3).
2.1.2. French Guyana Study. Seven tuberculin-positive and
6 tuberculin-negative HIV-negative controls without clinical
symptoms of tuberculosis were enrolled in the study. None
of them had suﬀered from active tuberculosis prior the
study, and the X-ray was normal for all of them. A total of
forty-five HIV-positive subjects without clinical symptoms
of tuberculosis were analyzed. Twenty-eight HIV-positive
subjects were classified in the category A of the CDC clas-
sification (without clinical symptoms of tuberculosis); sev-
enteen were tuberculin-positive and eleven were tuberculin-
negative. Seventeen HIV-positive subjects classified in the
category B of the CDC classification, suﬀering from either
varicella zoster or/and candidiasis (which are the most
frequent opportunistic infections in HIV-positive patients in
French Guyana), were also studied. Among them seven were
tuberculin positive and ten were tuberculin negative. Finally,
fourteen adult patients with active pulmonary tuberculosis
before multidrug therapy were monitored at the Centre
Hospitalier Andre´e Rosemon in Cayenne, French Guyana.
Six of these patients were HIV negative, and 8 were HIV
positive. All HIV negative, and seven HIV positive patients
were diagnosed with pulmonary tuberculosis whereas one
HIV-positive patient was diagnosed with extrapulmonary
TB. All subjects had been vaccinated with BCG at birth as
currently done in French Guyana. Informed consent was
obtained from the subjects, and the human guidelines given
by the Comite´ Consultatif de Protection des Personnes dans
la Recherche Me´dicale (CCPRB) from Guadeloupe were
followed.
2.2. Tuberculin Test. Subjects were injected intradermally
with 0.1mL of tuberculin (10 units, Tubertest, Sanofi
Pasteur) on the forearm. Reactions were determined by
measuring transverse diameter of induration 48/72 h after
administration. For HIV-positive subjects, an induration of
more than 5mm in diameter was considered as positive. For
HIV-negative subjects, an induration of more than 10mm
was considered as positive.
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2.3. Antigens. M. bovis BCG (strain GL2) was grown for
2 weeks as a surface pellicle on synthetic Sauton medium.
BCG culture filtrate (CF) was concentrated by ammonium-
sulfate precipitation (70% saturation), dialyzed against PBS,
sterilized by filtration, and stored at −20◦ as previously
described [22]. CF was used at a final concentration of
5 μg/mL. Purified protein derivate from M. tuberculosis
(PPD) (Statens Serum Institute, Copenhagen, Denmark) was
used at the concentration of 5 μg/mL (IFN-γ production)
or 25 μg/mL (lymphoproliferative assays). Native Ag85 com-
plex was purified from BCG culture filtrate by sequential
chromatography on phenyl-Sepharose and DEAE-Sephacel
(Pharmacia, Uppsala, Sweden) as previously described and
used at a final concentration of 10 μg/mL [27]. Phytohemag-
glutinin and Pokeweed Mitogen (both from Sigma, L’Isle
d’Abeau, France) were used as polyclonal T cell and T cell-
dependent B cell mitogen, respectively.
2.4. Lymphoproliferation Assays (Brussels Study). Hepar-
inized whole blood, collected by venipuncture, was diluted
1 : 10 in RPMI-1640 medium, supplemented with HEPES,
L-glutamine, penicillin/streptomycin, and 5 × 10−5 M 2-
mercapto-ethanol. Cells were cultured in round bottom
microwell plates (Greiner) in a humidified CO2 incubator
at 37◦ for 7 days. Tritiated thymidine (Amersham) was
added to the cells during the last 20 hours of culture.
Cells were harvested on a Skatron Cell Harvester, and
filters were counted in a Beckman LS Betaplate scintillation
counter. Mean counts per minute (cpm) were calculated
from quadruplicate cultures.
2.5. IFN-γ Production and IFN-γ Detection (Cayenne Study).
PBMCs were obtained by venipuncture, isolated on Ficoll-
Hypaque gradient (d = 1, 077), and suspended in RPMI
medium supplemented with 2mM L-glutamine, 100U of
penicillin/mL, 0.1mg of streptomycin/mL (all from Sigma),
and 10% human heat-inactivated serum from red blood cell
group AB. Cells were plated at 106/mL in flat-bottom 24-well
plates with or without antigens. The culture supernatants
were harvested after 7 days and stored at −20◦C. IFN-γ
levels were measured using specific IFN-γ sandwich ELISA
(sensitivity of 10 pg/mL) using NIB42 clone (mouse IgG1) as
capture antibody and 4SB2 clone (mouse IgG1) as detection
antibody (both from Pharmingen San Diego, CA).
2.6. Statistical Analysis. Student’s t-test was used for statis-
tical evaluation. Statistical analysis was done on log10 values
of IFN-γ titers, and IFN-γ titers below 10 pg/mL were con-
sidered as 0.1 log10 for statistical calculations. Proliferative
responses were analyzed using GraphPad Prism 4 software.
3. Results
3.1. Study Participants. Table 1 shows a summary of the
diﬀerent participant groups from Belgium (Brussels study)
and French Guyana (Cayenne study) analyzed in this study.
All work was conducted in accordance with the Declaration
Table 1: Study participants.
Brussels Cayenne
HIV− Tuberculin − 15 6
Tuberculin + 23 7
Tuberculosis — 6
HIV+ CDC-A
tuberculin − — 11
tuberculin+ 17 17
CDC-B
tuberculin − — 10
tuberculin + — 7
Tuberculosis
Pulmonary 3 7
Extrapulmonary 5 1
Eﬀusion 2 —
NTM infection 7 —
Number of subjects tested in each group in the two locations.
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Figure 1: Proliferative responses (mean cpm) in response to PPD,
CF from BCG, purified Ag85, and Pokeweed Mitogen in healthy
tuberculin-positive (n = 23) and tuberculin-negative HIV-negative
(n = 15) volunteers, as measured after 7 days of culture, using a
whole blood assay (heparinized blood diluted 1 : 10).
of Helsinki. Experiments were performed with the under-
standing and the consent of the human subjects and with
approval of the two local Ethical Committees.
3.2. Lymphoproliferative Responses of HIV-Negative and HIV-
Positive Subjects (Brussels Study). In order to determine
threshold values for positivity, 23 healthy tuberculin-positive
and 15 tuberculin-negative subjects (all HIV-negative) were
tested for their in vitro lymphoproliferative response using
a diluted whole blood assay. As shown in Figure 1, prolifer-
ative responses upon stimulation with PPD, culture filtrate
from BCG, and purified Ag85 complex from BCG culture
filtrate were significantly higher in the tuberculin-positive
(Mantoux+) than in the tuberculin-negative (Mantoux−)
group (P < .01), whereas no diﬀerence was observed
following stimulation with polyclonal PWM (P = .936).
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Figure 2: Lymphoproliferative response against PPD, Ag85, and PWM in HIV-negative/tuberculin-positive, HIV-positive/tuberculin-
positive, HIV-positive patients with TB and HIV-positive patients with MOTT disease. Proliferative responses (mean cpm of quadruplicate
cultures) as measured after 7 days of culture, using a whole blood assay (heparinized blood diluted 1 : 10).
Next, responses in these HIV-negative, tuberculin-
positive subjects were also compared to proliferative respons-
es in asymptomatic HIV-positive subjects latently infected
with M.tuberculosis (TST >5mm), in ten AIDS patients suf-
fering from active tuberculosis, and in seven AIDS patients
suﬀering from disease caused by mycobacteria other than
tuberculosis (MOTT/NTM). In vitro proliferative responses
to PPD of HIV-negative and HIV-positive subjects with a
positive tuberculin skin test were not significantly diﬀerent
between the two groups (mean ± SEM: 45, 940± 5, 255 (n =
23) cfr 34, 220 ± 6, 571 (n = 17) P = .167) (Figure 2(a)).
Responses to CF were not significantly diﬀerent either (data
not shown). In contrast,in vitro proliferative responses to
purified Ag85 (Figure 2(b)) were significantly higher in the
HIV-negative than in the HIV-positive group (21, 870 ±
4, 904 (n = 23) cfr 7, 775 ± 2, 360 (n = 17), P < .05). Using
a cutoﬀ value of 907 cpm (mean + 2 SD values of Ag85-
specific responses of 15 HIV-negative/tuberculin-negative
volunteers, Figure 1), only 10/17 (59%) of the HIV-positive
subjects demonstrated a positive proliferative T cell response
to Ag85. Likewise, responses to the polyclonal mitogen
PWM (Figure 2(c)) were also significantly higher in the HIV-
negative group than in the HIV-positive group (17, 780 ±
3, 520 (n = 17) cfr 6, 330 ± 2, 078 (n = 15), P < .05).
Finally, lymphoproliferative responses were also exam-
ined in AIDS patients with clinical signs of active tuberculosis
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Table 2: IFN-γ production of PBMC from tuberculin-positive and tuberculin-negative, HIV-negative and HIV-positive subjects.
HIV negative HIV positive (CDC-A)
Stimulus tuberculin + tuberculin – tuberculin + tuberculin –
(7) (6) (17) (11)
PPD 2417± 662∗,◦ 157± 56 852± 369∗∗ 238± 70
CF 1988± 576∗ 86± 28 1210± 503∗∗ 176± 63
Ag85 1644± 672∗ 26± 12 1141± 456∗∗ 84± 20
PHA 2635± 845 2885± 525 3281± 1842 2637± 1355
IFN-γ production in day 7 culture supernatants from purified PBMC. Results are expressed as mean ± standard deviation (pg/mL).
∗Significantly diﬀerent from healthy tuberculin-negative/HIV-negative controls (P < .05).
∗∗Significantly diﬀerent from healthy tuberculin-negative/HIV-positive controls (P < .05).
◦Significantly diﬀerent from healthy tuberculin-positive/HIV-positive controls (P < .05).
or NTM (MOTT) disease. Using a cutoﬀ value of 3,627 cpm
(mean + 2 SD values of PPD-specific responses of 15 HIV-
negative/tuberculin-negative healthy volunteers), positive
responses to PPD could be detected in 6/10 (60%) of HIV-
positive tuberculosis patients (19, 860±8, 779) (Figure 2(a)).
Proliferative responses against Ag85 (Figure 2(b)) were much
more dramatically aﬀected and positive only in two patients
(actually the two patients suﬀering from pleural eﬀusion)
(mean (n = 10): 11, 520 ± 7, 444; mean (n = 8) 485 ± 408).
Responses to PWM (Figure 2(c)) were finally also strongly
depressed in 9/10 patients (1, 334± 593).
Reflecting their dramatic decrease in CD4+ counts
(mean: 11/mm3), AIDS patients diagnosed with NTM
(MOTT) disease were completely unreactive to all antigens
tested (PPD: 147 ± 41; Ag85: 105 ± 32; PWM 104 ± 31)
(Figures 2(a), 2(b), and 2(c), resp.).
3.3. IFN-γ Responses of HIV-Negative and HIV-Positive
(CDC-A) Subjects (Cayenne Study). In vitro IFN-γ produc-
tion was analyzed in Cayenne in a 7-day cultured supernatant
of purified PBMC from 13 HIV-negative controls with either
a positive (n = 7) or a negative (n = 6) tuberculin skin test.
Confirming the proliferative responses, purified PBMC from
tuberculin-positive controls produced statistically higher
IFN-γ levels than tuberculin-negative controls for all the
mycobacterial antigens tested. (Table 2, P < .05). On the
other hand, IFN-γ levels in response to PHA were not statis-
tically diﬀerent in these two groups of HIV-negative controls.
Next, IFN-γ production was analyzed in 28 HIV-pos-
itive controls without clinical symptoms of tuberculo-
sis. Seventeen were tuberculin positive, and eleven were
tuberculin negative. HIV-positive/tuberculin-positive sub-
jects produced significantly more IFN-γ than HIV-positive/
tuberculin-negative subjects upon stimulation with CF,
Ag85, or PPD, but not upon stimulation with PHA or PWM
(Table 2). The number of CD4+ T cells was not statistically
diﬀerent between both groups, that is, 498 ± 264/mm3 in
tuberculin-positive and 467 ± 286/mm3 in tuberculin-nega-
tive subjects, respectively.
Mean IFN-γ production in response to all mycobacterial
antigens tended to be higher in HIV-negative than in HIV-
positive skin test-positive persons (Table 2), but (in contrast
to the lymphoproliferative responses) this diﬀerence was only
significant in response to PPD.
3.4. IFN-γ Responses of PBMC Recovered from HIV-Negative
and HIV-Positive Subjects with Clinical Symptoms of Tuber-
culosis. IFN-γ production in response to diﬀerent mycobac-
terial antigens was also analyzed in HIV-positive (n = 8)
and HIV-negative (n = 6) patients suﬀering from active
tuberculosis. A cutoﬀ level for negative IFN-γ production to
each antigen was determined as less than the mean minus
two 2SD values of the IFN-γ level measured in tuberculin-
positive, HIV-positive, respectively, HIV-negative controls
without symptoms of tuberculosis (indicated by the grey
bars, calculated from results of Table 2). Using this threshold,
3 (50%) and five (83%) out of 6 HIV-negative patients
with active tuberculosis were unresponsive to CF and PPD,
respectively (Figure 3(b)). Confirming our previous findings
on larger groups of TB patients [20, 23], IFN-γ responses
to Ag85 were very low in HIV-negative patients with active
tuberculosis, and in this study actually all 6 were unrespon-
sive to Ag85. In the group of 8 HIV-positive patients with
active tuberculosis, 4 (50%) and 5 (66%) were unresponsive
to CF and PPD, respectively. All of these 8 patients were
unresponsive to Ag85 (Figure 3(a)). Both HIV-negative and
HIV-positive subjects with active tuberculosis responded
to PWM and PHA even if the IFN-γ titers in response
to PHA were lower in HIV-positive than in HIV-negative
tuberculosis patients (1940 ± 1689 pg/mL versus 4161 ±
2123 pg/mL in response to PHA; 3550 ± 1906 pg/mL versus
2625± 480 pg/mL in response to PWM). CD4+ T cell counts
in HIV-positive patients with active tuberculosis ranged from
97/mm3 to 740/mm3 (mean: 384 ± 277/mm3). Since all
the HIV-positive (and negative) patients with tuberculosis
were unresponsive to Ag85, their inability to react with this
antigen was clearly not related to the CD4+ T cell count.
Altogether these results confirm the notion that the inability
to produce IFN-γ in response to Ag85 is a characteristic of
active tuberculosis, irrespective of HIV coinfection [23].
3.5. IFN-γ Response to Ag85 in HIV-Positive Patients with
Varicella Zoster and/or Candida Infections (CDC-B). IFN-γ
responses to Ag85 were also examined in tuberculin-positive
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Figure 3: Individual IFN-γ production (pg/mL) by PBMC in
response to diﬀerent antigens from HIV-positive (a) or HIV-
negative (b) patients with active tuberculosis. A negative response
was considered as less than mean −2SD of the IFN-γ production by
PBMC from tuberculin-positive/HIV-positive (a) and tuberculin-
positive/HIV-negative (b) controls. The circle patients with active
tuberculosis. The grey rectangle mean± 2SD of the IFN-γ produced
by PBMC from tuberculin-positive/HIV-positive or HIV-negative
controls.
and tuberculin-negative HIV-positive patients with varicella
zoster or candida infections (CDC-B) that are the most
common opportunistic infections observed in HIV patients
in French Guyana. Among the 10 tuberculin-negative/HIV-
positive CDC-B subjects, 9 (90%) were unresponsive to
Ag85. Furthermore, seven (70%) were unresponsive to CF,
and 8 (80%) to PPD (Figure 4(b)). Among the 7 tuberculin-
positive/HIV-positive CDC-B subjects, 2 (29%) were
unresponsive to Ag85. On the other hand, all were respon-
ders to PPD and CF (Figure 4(a)). IFN-γ responses to PHA
were not diﬀerent in tuberculin-positive from tuberculin-
negative HIV-positive persons suﬀering from varicella zoster
and/or candidiasis (1471 ± 1104 and 1881 ± 1196 pg/mL,
resp.). Furthermore, even if the CD4+ T cell counts were
lower in the tuberculin-negative group (272 ± 190/mm3)
than in the tuberculin-positive group (400± 146/mm3), this
diﬀerence was not significant. The unresponsiveness to Ag85
in 2/7 of these tuberculin-positive subjects in the absence of
clinical signs of tuberculosis was suggestive of a subclinical
infection with mycobacteria. To test this hypothesis, the 7
patients were reexamined one year later. During this year,
two of them developed a biologically confirmed infection
with mycobacteria, one with M. tuberculosis and one with
M. fortuitum. Interestingly, these two patients were precisely
those who were unresponsive to Ag85 the previous year.
3.6. Development of Tuberculosis in Tuberculin-Positive HIV-
Positive Subjects (CDC-A) Is Associated with Decreased Ag85-
Specific Responses. Five tuberculin-positive/HIV-positive
subjects (CDC-A) were examined at month 0, 3, 6, 9, and
12 for their IFN-γ production in response to Ag85 and
for clinical signs of tuberculosis. As shown in Figure 5, all
five subjects mounted a positive IFN-γ response to Ag85
at the beginning of the followup. Two out of five subjects
maintained their responsiveness to Ag85 and remained free
of clinical symptoms. In contrast, one subject showed a
moderate and two subjects showed a dramatic decrease in
IFN-γ in response to Ag85, and all three presented with signs
of clinical tuberculosis at the end of the 12-month follow-up
period.
4. Discussion
A major challenge in tuberculosis control is a better under-
standing of latent M. tuberculosis infection. Indeed, many
adult TB cases result from the reactivation of an initially con-
trolled latent M. tuberculosis infection. A defective immune
system, caused by iatrogenic immunosuppression, poverty-
related malnutrition, stress, ageing, and genetic factors
provide the basis of this reactivation. Infection with the
human immunodeficiency virus is another very important
risk factor for developing clinical tuberculosis, particularly in
third-world countries of the South. It is estimated that more
than one third of HIV-positive individuals are coinfected
with M. tuberculosis, and approximately 12% of AIDS deaths
are due to TB [3, 28]. M. tuberculosis reactivation in HIV-
coinfected subjects is generally observed at a 65 to 75% drop
in CD4+ T cell counts, which is actually much earlier than for
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Figure 4: Individual IFN-γ production (pg/mL) in PBMC in response to diﬀerent antigens from tuberculin-positive (a) or tuberculin-
negative (b) HIV-positive CDC-B subjects suﬀering from varicella zoster and/or candidiasis. A negative response was considered as less than
mean −2SD of the IFN-γ production by PBMC from healthy tuberculin-positive (a) and tuberculin-negative (b) HIV-positive controls. The
circle: subjects with varicella zoster and/or candidiasis (category B of the CDC classification). The grey rectangle: mean ± 2SD of the IFN-γ
produced by PBMC from tuberculin-positive (a) and tuberculin-negative (b) HIV-positive controls.
the classical opportunistic infections caused by mycobacteria
other than tuberculosis, such as bacteria of the M. avium-
intracellulare complex.
Even though tuberculosis preventive therapies can oﬀer
a short-term eﬀect in reducing the incidence of TB for HIV-
infected adults, they are not eﬀective in delaying HIV disease
progression to AIDS. Thus, in a randomized controlled trial
of 1053 HIV-positive Zambian adults receiving isoniazid for
6 months or rifampicin plus pyrazinamide for 3 months,
both preventive treatment regimens protected against tuber-
culosis for at least 2.5 years but appeared to have no eﬀect
on HIV progression or mortality [29]. Similar findings
were reported in a randomized placebo-controlled trial in
Kampala, Uganda on 2,736 PPD-positive and anergic HIV-
infected adults treated with isoniazid (INH) for 6 months,
INH plus rifampicin for 3 months, or INH plus rifampicin
plus pyrazinamide for 3 months [30, 31].
Here, we have analyzed mycobacteria-specific T cell
reactivity in M. tuberculosis-infected HIV-positive subjects
at diﬀerent stages of HIV progression. We observed that
lymphoproliferative memory T cell responses to the purified
mycolyl transferase Ag85 are impaired very early during
HIV infection at moments when T cell responses to crude
PPD and culture filtrate are still within the normal range
found in tuberculin-positive/HIV-negative healthy volun-
teers. Positive proliferative responses against Ag85 could be
detected in only 59% of the HIV-positive subjects, presenting
with a mean CD4+ count of more than 450/mm3. In
contrast, average Ag85-specific IFN-γ response in asymp-
tomatic tuberculin-positive subjects was not significantly
diﬀerent in the group of HIV-negative and HIV-positive
subjects (although there was a tendency to decrease) but
interestingly a follow-up analysis of these Ag85-specific IFN-
γ responses in five tuberculin-positive subjects classified as
CDC-A according to CDC classification [32] over a period of
one year indicated that decreased reactivity against Ag85 in
three of them coincided with reactivation and development
of clinical tuberculosis. Likewise, a followup in the group
of the seven tuberculin-positive subjects classified as CDC-B
showed development of clinical disease precisely in the two
subjects with initial low IFN-γ reactivity to Ag85. Despite
the limited number of subjects in this followup, our results
strongly suggest a protective role of Ag85-specific T cell
responses in the control of M. tuberculosis infection.
Vaccination with live attenuated BCG is not recom-
mended in immunocompromised individuals. However,
boosting of the low Ag85-specific responses in these patients
using subunit vaccination could be an alternative, particu-
larly in patients with restored CD4+ T cell counts after highly
active antiretroviral therapy [33–35]. We have previously
demonstrated the feasibility of this approach in a preclinical
model of CD4 gene knockout mice, partially reconstituted
with CD4+ T cells and vaccinated with plasmid DNA
encoding Ag85A and Ag85B [36].
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Figure 5: Evolution of Ag85-specific IFN-γ response in 5 HIV-
positive latently infected subjects. Individual IFN-γ production
(pg/mL) of PBMC in response to Ag85 from 5 tuberculin-
positive/HIV-positive subjects at baseline t = 0 and 3, 6, 9, and
12 months later. T = diagnosis of active tuberculosis. Dashed line:
mean of IFN-γ production minus 2SD in tuberculin negative/HIV
positive subjects.
The tuberculin skin test lacks sensitivity, particularly in
HIV-infected individuals and has poor specificity because
of antigenic cross-reactivity of PPD with environmental
mycobacteria and the BCG vaccine. Only few studies in
immunocompromised subjects have used in vitro T cell-
based assays using purified mycobacterial antigens. Silveira
et al. reported on cell-mediated immune responses to five
purified mycobacterial antigens in Portuguese HIV-positive
and HIV-negative patients with pulmonary tuberculosis
[37]. Similar to our results, T cell responses to purified 30 kD
protein (the Ag85B component of the Ag85 complex) were
lower in the tuberculosis patients than in HIV-negative PPD-
positive healthy volunteers, irrespective of HIV infection.
Proliferative responses weremore strongly aﬀected than IFN-
γ secretion in that study as well. In Zambia, a highly endemic
country for tuberculosis, ex vivo IFN-γ ELISPOT to M.
tuberculosis-specific ESAT-6/CFP-10 proteins was found to
be more specific and possibly more sensitive than PPD-
based methods of detecting latent M. tuberculosis infection
in HIV-positive subjects [38]. Lymphoproliferative responses
and IFN-γ secretion to mycobacterial antigens ESAT-6 and
Ag85 were also studied in subjects participating in a phase III
randomized placebo-controlled trial of a BCG prime-boost
vaccine strategy (using whole inactivated Mycobacterium
vaccae) in Dar es Salaam, Tanzania [39]. Tanzanian HIV-
infected adults with CD4+ counts > 200/mm3 and primed
with BCG vaccine in childhood were analyzed. Among 1885
subjects screened, 635 (35%) were classified to have latent
TB (as indicated by a PPD skin test of >5mm) and 13
had active tuberculosis. Subjects with latent TB were more
likely to have a T cell response than TB patients. Proliferative
response to Ag85 was detected in only 18.7% of these latently
infected HIV-infected subjects [40]. In the Brussels study,
10/17 (59%) of the tuberculin-positive/HIV-positive subjects
demonstrated a positive proliferative response to Ag85. With
respect to Ag85-specific IFN-γ production, the Tanzanian
study found only 38,6% of latently infected subjects to react
to the antigen [41], whereas in our study all seventeen
tuberculin-positive, HIV-positive (CDC-A) subjects from
Cayenne were found to be reactive. The reason for this
lower reactivity levels in the Tanzanian study is not clear.
Besides the far smaller number of subjects in our study,
another factor may have been the low (0,5mcg/mL) antigen
concentration used in the Tanzanian study. Also, except for
one person, the subjects enrolled in our proliferative study
had not been vaccinated with BCG, whereas all subjects in
the Tanzanian study had been vaccinated with BCG.
5. Conclusion
We have demonstrated that Ag85-specific proliferative T
cell responses are decreased during M. tuberculosis-HIV-
coinfection, even in 40% of patients classified as CDC-
A and with a positive tuberculin skin test. Furthermore,
a one-year follow-up of twelve HIV-positive/tuberculin-
positive subjects indicated that decreasing IFN-γ reactivity
against Ag85 was associated with development of clinical
tuberculosis, highlighting the protective potential of this
antigen. It would be interesting to monitor Ag85-specific
proliferative IFN-γ T cell responses in HIV-infected subjects
latently infected withM. tuberculosis and treated preventively
with isoniazid to see whether Ag85-specific responses could
be stabilized. Attempting to stabilize these T cell responses
by postexposure vaccination might be an alternative. In this
context, a proof-of-concept Phase IIb clinical trial to evaluate
the protective eﬃcacy of a booster MVA85A vaccination
administered to healthy HIV-infected adults in South Africa,
Senegal, and The Gambia was started in February 2010
(EDCTP Annual report 2009).
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